Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria.

Nnaemeka C IriemenamFehintola A IgeStacie M GrebyAugustine MpamugoAdo G AbubakarAyuba B DawurungMudiaga K EsiekpeAndrew N ThomasMary U OkoliSamuel S AwalaBlessing N UgboajaChicago C AchugbuIfeanyichukwu OdohFelicia D NwatuTemitope OlaleyeLoveth AkayiOluwaseun O AkinmuleroJoseph DattijoEdewede OnokevbagbeOlumide OkunoyeNwando MbaNdidi P AgalaMabel UwanduMaureen AniedobeKristen Alyce StaffordAlash'le AbimikuYohhei HamadaMahesh SwaminathanMcPaul I OkoyeLaura C SteinhardtRosemary Ajuma Audu

Published in: PloS one (2022)

Our results showed overall lower sensitivity and a comparable specificity with the manufacturer's validation. There appears to be less cross-reactivity with NAIIS pre-pandemic COVID-19 specimens using the xMAP SARS-CoV-2 Multi-Antigen IgG assay. In-country SARS-CoV-2 serology assay validation can help guide the best choice of assays in Africa.

Keyphrases

sars cov
high throughput
respiratory syndrome coronavirus
coronavirus disease
single cell
ultrasound guided